Key result
Patient-reported outcome measures are vital in heart failure care and drug development, requiring further standardization and research to define minimal clinically important differences.
Why the study?
Heart failure consequences substantially impact patients' lives but are not routinely captured in clinical trials, highlighting the need to improve the use of patient-reported outcomes.
Answers are grounded in this paper and cite their sources.
Patient-reported outcomes are vital in heart failure care and drug development, requiring standardization, patient involvement, and routine collection in trials and practice.
There are many consequences of heart failure (HF), including symptoms, impaired health-related quality of life (HRQoL), and physical and social limitations (functional status). These have a substantial impact on patients' lives, yet are not routinely captured in clinical trials. Patient-reported outcomes (PROs) can quantify patients' experiences of their disease and its treatment. Steps can be taken to improve the use of PROs in HF trials, in regulatory and payer decisions, and in patient care. Importantly, PRO measures (PROMs) must be developed with involvement of patients, family members, and caregivers from diverse demographic groups and communities. PRO data collection should become more routine not only in clinical trials but also in clinical practice. This may be facilitated by the use of digital tools and interdisciplinary patient advocacy efforts. There is a need for standardization, not only of the PROM instruments, but also in procedures for analysis, interpretation and reporting PRO data. More work needs to be done to determine the degree of change that is important to patients and that is associated with increased risks of clinical events. This 'minimal clinically important difference' requires further research to determine thresholds for different PROMs, to assess consistency across trial populations, and to define standards for improvement that warrant regulatory and reimbursement approvals. PROs are a vital part of patient care and drug development, and more work should be done to ensure that these measures are both reflective of the patient experience and that they are more widely employed.
No takes yet. Share an insight, caveat, or question.
Zannad et al. (2023) conducted a review in Heart failure. Patient-Reported Outcome Measures was evaluated. Patient-reported outcome measures are vital in heart failure care and drug development, requiring further standardization and research to define minimal clinically important differences.
Synapse has enriched 10 related papers. Consider them for comparative context: